Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Resource for journalists around the world on COVID-19 vaccines
2021-11-22 16:49
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021
2021-11-22 08:16
Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index
2021-11-22 08:00
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
2021-11-21 17:09
CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China
2021-11-21 17:02
Nestle Health Science Partners with Healint to Initiate a Fully Virtual Study on Ketogenic Treatment for Migraines
2021-11-21 08:49
Successful 2020 Tang Prize Award Ceremony Highlights Laureates' Achievements and Influence
2021-11-20 15:00
US FDA Grants Breakthrough Designation for Early-Stage Breast Cancer Detection Blood Test Developed by Datar Cancer Genetics
2021-11-20 08:00
Vela Diagnostics expands automation options for SARS-CoV-2 RT-PCR Test
2021-11-20 01:15
SyneuRx Announces Oral COVID-19 Twindemic Antiviral Drug Candidate Pentarlandir Has Entered Final Portion of FDA Phase II Testing
2021-11-20 01:00
UAE to receive award from Parliamentary Assembly of the Mediterranean for Waterfalls Initiative
2021-11-19 21:33
Brii Biosciences Joins Hang Seng Composite Index
2021-11-19 19:06
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma
2021-11-19 19:00
YHLO Revealed Its New Development of CLIA Technology at MEDICA 2021
2021-11-19 14:43
111, Inc. Announces Third Quarter 2021 Unaudited Financial Results
2021-11-19 13:31
ASRA 2021 | Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
2021-11-19 13:14
Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day
2021-11-19 13:00
EQT Infrastructure to acquire Icon Group, Australia's largest integrated cancer care provider
2021-11-19 10:21
Fiji based Omnicare Successfully Adopts the Digital Health Platform Jointly Provided by EnoviQ and InsureMO
2021-11-19 10:00
Investment Confidence in Icon Group to Drive Next Phase of Global Growth With EQT Infrastructure Investment
2021-11-19 09:19
1
319
320
321
322
323
895